UnknownNot Applicable

APPETITE: linguAl PYY3-36 on aPpEtite and acuTe Energy InTakE

40 participantsStarted 2022-02

Plain-language summary

A double-blind, cross-over, placebo-controlled, proof-of-concept study using oral peptide YY3-36 solution to investigate the mechanistic role of lingual PYY in regulating appetite, energy intake and food preference in people with overweight/obesity. The aim of this study is to investigate the mechanistic role of lingual PYY in regulating appetite, energy intake and food preference in people with overweight/obesity.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Female subjects who are pregnant or breast-feeding.
✕. Female subjects of childbearing potential who are not on highly effective contraception.
✕. Post-menopausal women who have not had a period of spontaneous amenorrhea for more than 1 year.
✕. Previous bariatric surgery.
✕. Type 1 or 2 diabetes.
✕. Current use of weight loss medications or taking medication that affects appetite, e.g., antidepressants such as mirtazapine.
✕. Food intolerances, or allergies, that would make fixed energy meal and/or ad libitum meal unable to be performed.
✕. Impairment of sense of taste and/or smell, as per subject assessment and direct questioning.

What they're measuring

appetite scores

Timeframe: up to 6 hours

energy intake expressed as Kcal of eaten food

Timeframe: up to 6 hours

Trial details

NCT IDNCT05110664

SponsorUniversity College, London

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-08

Contact for this trial

Rachel L Batterham

02076790991 r.batterham@ucl.ac.uk

View on ClinicalTrials.gov More Obesity trials